FIELD: medicine.
SUBSTANCE: group of inventions relates to a method of reducing the incidence of one or more asthma exacerbations and to a method of reducing the incidence of asthma exacerbations or improving one or more asthma-related parameters. A method of reducing the incidence of one or more asthma exacerbations in a subject suffering from moderate-to-severe eosinophilic asthma is proposed, comprising administering to the subject an antibody or antigen-binding fragment thereof that specifically binds to the interleukin 4 receptor (IL-4R), where the said antibody or antigen-binding fragment contains three sequences of heavy chain complementarity determining regions (HCDRs) containing SEQ ID NOs: 148, 150 and 152, and three light chain complementarity determining regions (LCDR) sequences containing SEQ ID NO: 156, 158, and 160, and wherein the said antibody or antigen-binding fragment thereof is an additional maintenance treatment. Also a method is provided for reduction of the incidence of asthma exacerbations or improving one or more asthma-related parameters in a subject suffering from moderate-to-severe eosinophilic asthma, comprising sequentially administering to the subject a single initial dose of an antibody or antigen-binding fragment thereof that specifically binds to the interleukin 4 receptor (IL-4R), followed by one or more secondary doses of the said antibody or antigen-binding fragment thereof, wherein the said antibody or antigen-binding fragment thereof contains three heavy chain complementarity determining regions (HCDR) sequences containing SEQ ID NOs: 148, 150 and 152, and three light chain complementarity determining regions (LCDR) sequences containing SEQ ID NO: 156, 158, and 160, and wherein the said antibody or antigen-binding fragment thereof is an additional maintenance treatment.
EFFECT: above group of inventions provide targeted therapy methods for treating or preventing asthma.
3 cl, 31 dwg, 13 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
ANTIBODY FOR SPECIFIC BINDING WITH INTERLEUKIN 4 RECEPTOR | 2017 |
|
RU2774446C2 |
ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
IL-5 BINDING MOLECULE, METHOD OF ITS PREPARATION AND ITS USE | 2021 |
|
RU2811518C1 |
ANTI-IL-5 ANTIBODIES | 2017 |
|
RU2758008C2 |
ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
Authors
Dates
2023-08-10—Published
2013-08-20—Filed